A-Alpha Bio Partners with Novo Nordisk to Advance AI-Driven Protein Engineering

This collaboration will leverage high-throughput AlphaSeq datasets to train, fine-tune, and validate proprietary models that predict protein–protein binding affinities. The work will support de novo protein design, optimize multiple therapeutic scaffolds, and strengthen structural interaction databases, enabling faster discovery of protein therapeutics with improved affinity, specificity, and developability through large-scale experimental validation.